

2021-10-08

# The impact of smoking cessation on multiple sclerosis disease progression

Rodgers, J

<http://hdl.handle.net/10026.1/18884>

---

10.1093/brain/awab385

Brain

Oxford University Press (OUP)

---

*All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.*

# The impact of smoking cessation on multiple sclerosis disease progression

Jeff Rodgers,<sup>1,†</sup> Tim Friede,<sup>2,†</sup> Frederick W. Vonberg,<sup>3,†</sup> Cris S. Constantinescu,<sup>4</sup> Alasdair Coles,<sup>5</sup> Jeremy Chataway,<sup>6,7</sup> Martin Duddy,<sup>8</sup> Hedley Emsley,<sup>9,10</sup> Helen Ford,<sup>11</sup> Lennora Fisniku,<sup>12</sup> Ian Galea,<sup>13</sup> Timothy Harrower,<sup>14</sup> Jeremy Hobart,<sup>15</sup> Huseyin Huseyin,<sup>16</sup> Christopher M. Kipps,<sup>13</sup> Monica Marta,<sup>17,18</sup> Gavin V. McDonnell,<sup>19</sup> Brendan McLean,<sup>20</sup> Owen R. Pearson,<sup>21</sup> David Rog,<sup>22</sup> Klaus Schmierer,<sup>18,23</sup> Basil Sharrack,<sup>24</sup> Agne Straukiene,<sup>25</sup> Heather C. Wilson,<sup>26</sup> David V. Ford,<sup>1</sup> Rod M. Middleton<sup>1,†</sup> and Richard Nicholas<sup>1,3,27,†</sup> for The MS Register group

**†These authors contributed equally to this work.**

## Abstract

The negative impact of smoking in MS is well established, however, there is much less evidence as to whether smoking cessation is beneficial to progression in MS.

Adults with MS registered on the United Kingdom MS Register (2011-2020) formed this retrospective and prospective cohort study. Primary outcomes were changes in 3 patient reported outcomes (PROs): normalised MS Physical Impact Scale (MSIS-29-Phys), normalised MS Walking Scale (MSWS-12) and the Hospital Anxiety and Depression Scale (HADS-Anxiety and HADS-Depression). Time to event outcomes were clinically significant increases in the PROs.

7983 participants were included, 4130 (51.7%) of these had ever smoked; of whom 1315 (16.5%) were current smokers and 2815/4130 (68.2%) were former smokers. For all PROs, current smokers at the time of completing their first questionnaire had higher PRO scores indicating higher disability compared to those who had never smoked (~10 points difference in MSIS-29-Phys and MSWS-12; 1.5-1.8 point for HADS-anxiety and HADS-depression). There was no improvement in PRO scores with increasing time since quitting in former smokers.

923 participants formed the prospective parallel group, which demonstrated that MSIS-29-phy 5.03, [3.71, 6.34], MSWS-12 5.28, [3.62, 6.94] and HADS-depression 0.71, [0.47, 0.96] worsened over a period of 4 years, whereas HADS-anxiety remained stable. Smoking status was significant at year 4; current smokers had higher MSIS-29-Phys and HADS-Anxiety scores

(3.05 [0.22, 5.88], 1.14 [0.52,1.76]) while former smokers had a lower MSIS-29 score of -2.91[-5.03, -0.79].

4642 participants comprised the time to event analysis. Still smoking was associated with a shorter time to worsening event in all PROs (MSIS-29-Phys: n=4436, p=0.0013; MSWS-12: n=3902, p=0.0061; HADS-anxiety: n=4511, p=0.0017; HADS-depression: n=4511, p<0.0001). Worsening in motor disability (MSIS-29-Phys and MSWS-12) was independent of baseline HADS-anxiety and HADS-depression scores. There was no statistically significant difference in the rate of worsening between never and former smokers.

When smokers quit, there is a slowing in the rate of motor disability deterioration so that it matches the rate of motor decline in those who have never smoked. This suggests that smoking cessation is beneficial for people with MS.

### **Author affiliations:**

1 Population Data Science, Swansea University Medical School, Swansea, SA2 8PP, UK

2 Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.

3 Department of Cellular and Molecular Neuroscience, Imperial College London, W12 0NN, UK

4 Division of Clinical Neuroscience, University of Nottingham, Nottingham, NG7 2UH, UK

5 Cambridge Neuroscience, University of Cambridge, Cambridge, CB2 3EL, UK

6 Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom WC1B 5EH

7 National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, W1T 7HA, UK

8 Neurosciences, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, NE7 7DN, UK

9 Lancaster Medical School, Faculty of Health & Medicine, Lancaster University,

10 Lancaster, UK & Department of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, PR1 2HE, UK

11 Centre for Neurosciences, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX

12 Brighton and Sussex University NHS Trust, BN1 6AG, Brighton

13 Clinical Neurosciences, Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO17 1BJ, UK

14 Royal Devon and Exeter NHS Trust, Barrack Road, Exeter, EX25DW, UK

15 Plymouth University Peninsula Schools of Medicine and Dentistry, Consultant Neurologist, University Hospitals Plymouth, Room N13 ITTC Building, Plymouth Science Park, Davy Road, Plymouth, Devon, PL6 8BX, UK

16 Luton and Dunstable University Hospital, Bedfordshire Hospitals NHS Foundation Trust, Lewsey Road, Luton, LU4 0DZ, UK

17 Neurology - Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea SS0 0RY, UK

18 Blizard Institute, Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, UK

19 MS Clinic, Belfast City Hospital, BHSC, Belfast, BT9 7AB, UK

20 The Royal Cornwall Hospitals NHS Trust, Treliske, Truro TR1 3LJ, UK

21 Swansea Bay University Health Board, Swansea, SA6 6NL, UK

22 Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK

23 Clinical Board Medicine (Neuroscience), Barts Health NHS Trust, The Royal London Hospital, London, UK

24 Department of Neurology and NIHR Neurosciences Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, S10 2JF, UK

25 Torbay and South Devon NHS Foundation Trust, Torquay, TQ2 7AA, UK

26 National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1H 3BG, UK

27 Department of Visual Neuroscience, UCL Institute of Ophthalmology, London, EC1V 9RL, UK

Correspondence to: Prof Richard Nicholas

Faculty of Medicine, Imperial College London, Charing Cross Campus, Fulham Palace Road,  
London, W6 8RF, UK

E-mail: r.nicholas@imperial.ac.uk

**Keywords:** multiple sclerosis; public health; epidemiology

**Abbreviations:** ANCOVA = Analysis of Covariance; DMT = Disease Modifying Therapy;  
EDSS = Expanded Disability Status Scale; HADS = Hospital Anxiety and Depression Scale;  
IQR = Interquartile Range; MS = Multiple Sclerosis; MSIS-29 = Multiple Sclerosis Impact  
Scale; MSWS-12 = MS Walking Scale; NHS = National Health Service; PRO = Patient  
reported outcome; pwMS = people with multiple sclerosis; REC = Research Ethics  
Committee; SD = Standard Deviation; UKMSR = United Kingdom MS Register

## Introduction

Retrospective studies have shown that people with MS (pwMS) who smoke have more significant motor symptoms<sup>1</sup>, increased MRI activity and brain atrophy<sup>2,3</sup> and more cognitive and psychological impairment<sup>4,5</sup>. In relapsing MS smoking can lead to earlier death<sup>6</sup>, reaching disease milestones earlier<sup>7</sup> and earlier onset of secondary progressive MS<sup>8,9</sup>. While the negative impact of smoking in MS is well established, there is less evidence whether smoking cessation is beneficial. Retrospective analyses have shown that smoking cessation may reduce the risk of reaching disability milestones<sup>9</sup>, and quitting earlier is associated with stronger reductions in risk<sup>5</sup>. These milestones, however, are confounded by other factors such as mood

10

Studying the effects of exposures known to be harmful, such as smoking, poses specific challenges. One approach is to use registry data where the self-directed choice of each study subject determines their exposure. Registry studies are subject to several biases, in particular those associated with geographical and temporal variations in data-collection<sup>11</sup>. Some cross-site and longitudinal stability can be introduced by the use of patient reported outcomes (PROs) in which participants answer questions about certain aspects of their own health. PROs are not widely used as standardised clinical outcome measures in MS and preference has been for tools such as the Expanded Disability Status Scale (EDSS). However, PROs have been shown to be the better predictor of outcome when integrated into a patient-specific, personalised approach<sup>12</sup>. Two validated PROs have established use in assessing the motor impact of MS: the MS walking scale 12 (MSWS-12)<sup>13</sup>, and the motor component of the MS impact scale 29 (MSIS-29-Phys)<sup>14</sup>. Clinically relevant changes, corresponding to established EDSS outcomes, have been validated both for the MSWS-12<sup>15</sup> and the MSIS-29<sup>16,17</sup>. The MSIS-29 has also been correlated with mortality<sup>18</sup>.

The United Kingdom MS Register (UKMSR) is a primarily patient-driven registry of PRO based data that has been active since 2011. We have used UKMSR data from almost 8000 participants to conduct a PRO-based study investigating the effects of smoking, and of smoking cessation, in pwMS. To our knowledge, this represents the largest investigation into the effects of smoking cessation in MS and the largest study of smoking in any neurological disease to use PROs. We have used MSWS-12, MSIS-29-Phys and hospital anxiety and depression scales (HADS)<sup>19</sup>. Firstly, we utilised historical data on smoking and smoking cessation to assess

current impact on functional status. We then used prospectively collected data in the same cohort yearly over 4 years to measure average change in the PROs. Finally, we modelled the PRO results for use in time to event analyses using confirmed clinically relevant worsening events, to dissect out the impact of smoking and smoking cessation on disease progression in MS.

## Methods

### *Population demographics*

The UKMSR is an online, UK-wide register supported by National Health Service (NHS) clinical centres (REC: South West Central Bristol NRES 16/SW/0194). The register includes independent verification of treatments and EDSS outcomes from NHS centres in a separate but overlapping population. Participants enter data regularly (3 monthly from 2011 to 2018 and 6 monthly subsequently) and are sent reminders by email. Since September 2018 participants have a 28-day window in which to complete the PROs, although often they are all completed in one day. For this study demographics and disease specific data were assessed at the first questionnaire (baseline) or within 12 months prior or 6 months after completion of the first questionnaire. Demographic data collected included age, gender, ethnicity (Black Asian or minority ethnic group (BAME)/not). Disease-specific data was also obtained, including disease length (in years, from initial symptoms), disease type at diagnosis (secondary and primary progressive/not progressive) and whether the participant was on a disease modifying treatment (DMT) or not for their MS (highly active/normally active/none). Highly active treatments were defined as: alemtuzumab, cladribine, daclizumab, fingolimod, mitoxantrone, natalizumab, crelizumab, ofatumumab, and rituximab. A univariate statistical analysis was completed on these data; Chi-squared test for categorical, one way ANOVA tests for comparison of parametric means and Kruskal-Wallis tests for non-parametric data.

### *PRO Questionnaires*

Three PROs were used: MSIS-29-Phys, MSWS-12 and the HADS scale. The MSIS-29-Phys subscore version 1 (MSIS-29v1<sup>14</sup>) was used prior to April 2012, and version 2 (MSIS-29v2<sup>20</sup>) was used subsequently. Answers to the 20 questions that form the MSIS-29 Phys sub-score are each scored between 1 and 5 in version 1, and between 1 and 4 in version 2. These scores give a total ranging from 20 to 100 for MSIS-29v1, and of 20 to 80 for MSIS-29v2. In order to account for the changes in scales, totals were rescaled to a value in the range of 0 to 100 using

a unity-based normalisation procedure<sup>21</sup>. A 10-point increase in the normalised score corresponds to an 8-point increase in the MSIS-29v1 physical score. This change reflects clinically relevant worsening<sup>16,17</sup>. MSWS-12 version 2<sup>13</sup> was used to assess walking function. Participants were only excluded from the MSWS-12 assessment if they indicated that they could not walk. The score was normalised as above. A 10-point change in the normalised score corresponds to a 5.4-point change in the raw score which reflects a clinically relevant change<sup>15</sup>. The HADS provides scores for anxiety and depression<sup>19</sup>. A 2-point change in either of these sub-scores corresponds to a clinically relevant change<sup>22</sup>.

### ***Retrospective and prospective cohort study design***

The retrospective analysis was conducted using the population in whom valid data was available for date of birth, gender, and smoking status. Participants needed to have answered at least one of the three PROs and the first questionnaire answered for each PRO was used.

Two approaches were taken for the prospective cohort analysis. In the first, for the 4-year prospective parallel group analysis, participants were identified who had completed each of the 3 PROs at baseline and every year ( $\pm 60$  days) over a 4-year period. Secondly, for the time to event analyses 'streaks' of longitudinal data were obtained from participants who fulfilled specific criteria. To be included in a streak, participants had to have completed at least three sets of PRO questionnaires. The minimum time interval between each questionnaire was 15 days and the maximum interval could not be longer than 240 days. The longest sequence of questionnaires completed by each participant defined by these criteria was selected for each participant. In the event that a participant had more than one longest streak (of equal length), then the most recent was chosen. A separate set of streaks was built for each questionnaire. Clinically significant step changes were used as 'events' for time to event analysis. Information about the time to event was provided from timestamps which were automatically appended by the database tables. Censoring occurred at the date when the PRO score increased by a clinically significant step or, alternatively, when the last questionnaire of the streak was completed. The maximum number of PROs answered was used as a confounding variable in the time to event analysis.

### ***Smoking status***

Questions about smoking status were available to answer at any time and were reviewable at the time of every email reminder when the regular battery of PROs were completed. Participants were asked if they had ever smoked and, if they answered yes, whether they



continued to smoke. This provided three distinct categories: never, former, and current smoker. If the participant answered that they had stopped smoking, then the cessation date was requested. The number of cigarettes smoked per day in current and former smokers was also requested. This was classified as light ( $\leq 7$ ), moderate (7-12) and heavy ( $\geq 13$ ) based on the distribution of the data. Pack years smoked is defined by the rate of daily smoking in percentage of standard 20 cigarette packs multiplied by the total time smoked in days.

### ***Statistical analysis***

All statistical analysis was performed using the R statistical programming language, version 3.5.1, in the RStudio environment, version 1.1.463. Boxplots were used to illustrate the retrospective analysis (minimum score, lower quartile, median, upper quartile, maximum score). Generalised linear modelling was used for the retrospective analysis and Cox regression modelling was used to analyse the effects of being a never-, current- and former smoker on the rate of clinically significant events using the 'survival' package (v2.43-3) in R (v3.5.3). Baseline variables considered were age at first assessment, disease length, MS type at diagnosis (progressive as reference vs not progressive), gender (female as reference), ethnicity group (BAME vs white) and pack years smoked. DMT, either highly active, normally active or none, was modelled as a time varying covariate. Linear mixed models for repeated measures were used to analysis the prospective parallel groups using the 'lme4' package (v1.1-7) optimised using restricted maximum likelihood estimates. Dependent variables were the normalised MSIS-29 Phys, MSWS-12, HADS anxiety and depression scores. Fixed effects for time, smoking status, age, gender, time since onset, treatment type, pack years, and ethnicity were added, as well as the interaction terms between time and smoking status. The study participants were included as a random effect. Estimates of the fixed effects and their 95% confidence intervals are reported.

### ***Data availability***

Access to the data for this study is available in a secure environment subject to governance approval.

## **Results**

### ***Demographics***

Seven thousand nine hundred and eighty-three pwMS who had a valid smoking status and had completed at least one PRO were identified from the UKMSR database (n=16187; valid date

of birth and gender). Details of the excluded population is provided in supplementary Table 1. Four thousand six hundred and forty-two pwMS in turn had the required information to produce a streak of prospective time to event data. For the 4-year prospective parallel cohort analysis 923 pwMS were available given the selection criteria (Table 1). Using simultaneously collected data (N=4591) we confirmed that the MSIS-29-Phys was highly correlated with the MSWS-12 ( $r=0.87$ , 95%CI [0.86, 0.87]). MSIS-29 was less so with the HADS-depression ( $r=0.61$ , 95%CI [0.59, 0.63]) and HADS-anxiety ( $r=0.37$ , 95%CI [0.35, 0.40]). The correlation of the MSWS-12 to the HADS-depression was higher ( $r=0.50$ , 95%CI [0.48, 0.53]) than the MSWS-12 correlation with the HADS-anxiety ( $r=0.21$ , 95%CI [0.18, 0.23]). HADS-depression and HADS-anxiety was also correlated with each other ( $r=0.60$ , 95%CI [0.59, 0.62]).

### ***Smoking prevalence in the UKMSR population***

Smoking status was independently verified in our data provided by NHS clinical centres. There were 858 pwMS who had smoking data on both the portal submitted by pwMS and in records collected by their clinical team. Of these, 265 records were independently collected within two months of each other since 2015. In the clinical data 11.0% were current smokers versus 14.7% for the online portal ( $p = 0.0491$ ); 10 pwMS had told their healthcare team they do not smoke but revealed they did smoke on the portal.

4130/7983 (51.7%) of the total MS population were ever smokers; 1315/7983 (16.5%) were current smokers which is similar to the 10-year average prevalence across the entire UK from 2011 (16.68%,  $p = 0.619$ )<sup>23</sup> 2815/4130 (68.2%) of the smokers had stopped at the time of data collection; this proportion is higher than for the total UK population between 2011 and 2019, (57.2%,  $p = <0.001$ ). In the time to event population, 675/4642 (14.5%) were current smokers and 130/923 (13.7%) of the 4-year prospective population were current smokers. As the populations studied became more selective and required longer follow-up (total > time to event > 4-year parallel group) age and disease length increased as did the proportion of pwMS with progressive diagnoses but also the proportion of males (Table 1).

### ***Retrospective analysis of smoking impact***

The total population was used for the retrospective analysis ( $n=7983$ ; Table 1). For all PROs, those who were current smokers at the time of completing their first questionnaire had higher disability, depression and anxiety compared to those who had never smoked (Figure 1A). Smoking cessation was associated with a range of PRO scores depending on the PRO. HADS-

depression scores were similar in former smokers compared to never smokers (Fig1A-panel 4). MSIS-29-Phys and HADS-anxiety scores were lower in former smokers than those of current smokers but higher than those of never smokers (Fig1A-panels 1 and 3). There was no change in the MSWS-12 scores compared to current smokers (Fig1A-panel 2). In those who were still smoking, heavier smoking burden (light, moderate, heavy) was associated with a higher PRO score in all cases (Figure 1B). In those who were former smokers, the effects of increased smoking burden were still evident except for in the HADS-anxiety score (Figure 1C). PRO score was not correlated with time since quitting in former smokers in all PROs; MSIS-29-Phys ( $r=0.04$ , 95%CI [0.003, 0.078],  $n=2754$ ), MSWS-12 (0.11, 95%CI [0.07, 0.15],  $n=2581$ ), HADS anxiety Score (-0.19, 95%CI [-0.22, -0.15],  $n=2779$ ) and HADS depression score (-0.08, 95%CI [-0.11, -0.04],  $n=2779$ ).

Carrying out a multi variable linear regression adjusting for age at baseline, time since onset, MS type at diagnosis, ethnicity and whether the subject was receiving a DMT (Table 2) confirmed the expected impact of age and disease length and having progressive disease on PRO scores but also demonstrated benefits of being on a DMT and being non-white. The analysis confirmed that smokers had higher PROs scores than never smokers with a mean increase in 4.7 and 3.7 points for the MSIS-29-Phys and MSWS-12 respectively and 0.79 and 0.74 for the HADS-anxiety and depression respectively. There was no significant difference between former smokers and never smokers in any of the PROs. However, for each additional pack year of smoking there was a significant increase in all PROs: 0.19 point for the MSIS-29-Phys, 0.21 point for the MSWS-12 and 0.03 points for both HADS scores indicating a cumulative effect of smoking on disability.

### ***Prospective parallel group analysis of smoking impact over 4 years***

To determine the impact of smoking on PROs over the longer term we utilised a subgroup of pwMS ( $n=923$ ; Table 1) who had completed the PROs every year over 4 years. Average scores were plotted for each category of smoking status (Figure 2). The MSIS-29-phy, MSWS-12 and HADS-depression score worsened over time whereas the HADS anxiety remained stable. Smoking status was significant controlling for time across all PROs. Linear mixed modelling demonstrated that at year 4 MSIS-29-Phys (5.03, [3.71, 6.34]), MSWS-12 (5.28, [3.62, 6.94]), and HADS-Depression (0.71, [0.47, 0.96]) scores increased whereas the HADS-Anxiety did

not change. Being a current smoker was associated with a higher score than never smokers for MSIS-29-Phys 3.05 [0.22, 5.88] and HADS-Anxiety 1.14 [0.52, 1.76], whereas former smokers had a lower score at year 4 by -2.91 [-5.03, -0.79] MSIS-29-Phys points. Average scores for MSIS-29, MSWS-12 and HADS depression increased steadily for each year after baseline when accounting for both fixed and random effects (see supplementary Table 2 for full results).

### ***Time to event analyses***

The prospective time to event analysis was performed using streaks of data created using the criteria described above. Streak length ranged from 180 days to 8 years. Median streak length (in years) for MSIS-29-Phys was 3.22 (interquartile range (IQR) 3.65), MSWS 2.82 (IQR 3.65) and HADS 3.19 (IQR 3.63). Median time (in days) between each questionnaire in the streak was 115 (IQR 77) for the MSIS-29-Phys, 111 (IQR 65) for the MSWS and 114 (IQR 74) for the HADS.

Cumulative event probabilities for time to worsening event were calculated for each PRO (Figures 3 and 4). Cox regression models were created for time to worsening, controlling for age at baseline, gender, baseline score, MS type at diagnosis with DMT treatment as a time-varying covariate (Table 3). Together, these demonstrated that current smoking was associated with a shorter time to worsening of MSIS-29-Phys (Table 3, Figure 3A), MSWS-12 (Table 3, Figure 3B), HADS-anxiety events (Table 3, Figure 4A) and HADS-depression (Table 3, Figure 4B). There was no significant difference in the rate of events between never and former smokers.

### ***The relationship between anxiety, depression and motor events.***

The HADS-anxiety and HADS-depression PROs were separately modelled against each motor PRO (Table 4). 1860 participants shared time to event data starting at the same time for all PROs. Using Cox modelling controlling for baseline MSIS-29-Phys (Table 4, column 1) and MSWS-12 (Table 4, column 2) score, age, gender, MS Type at diagnosis, ethnicity and DMT as a time-varying covariate, current smoking was associated with an increased risk of having a higher MSIS-29-Phys and MSWS-12 score independently of the baseline HADS-anxiety and HADS-depression score. An increasing baseline HADS-depression score was independently associated with a worsening of both the MSIS-29-Phys and MSWS-12. Next, we used Cox models to investigate the impact of the MSIS-29-motor on the HADS-anxiety (Table 4, column

3) and HADS-depression scores (Table 4, column 4). In both cases, being a current smoker was associated with a higher MSIS-29-Phys score and HADS-anxiety score controlling for age, gender, MS Type at diagnosis, ethnicity and DMT as a time-varying covariate.

## Discussion

The UK MS Register has enabled the identification of a UK wide, community-based registry population of almost 8000 people to demonstrate the benefits of smoking cessation in MS. Smoking is associated with a dose related worsening of motor function and smokers experience an accelerated rate of worsening compared to non-smokers. Once accrued, the damage does not resolve when smoking is stopped. Importantly however, we have shown that, following smoking cessation, there is a deceleration in the rate of motor deterioration so that it matches the rate of motor decline in those who have never smoked.

The use of registry data has allowed us to overcome some of the challenges associated with studying harmful interventions. The use of PROs has, in turn, negated some of the limitations which are associated with registry data. One drawback of registry data is the potential variability associated with data drawn from multiple sites and multiple operators. This variability is particularly true of the EDSS, a quantifiable neurological examination and the most commonly used outcome in MS<sup>24</sup>. The use of validated PROs has allowed a more uniform UK-wide approach to data collection. It is especially reassuring that the retrospective analysis highlights the known benefits of DMTs in MS as this has previously been shown with other registries using the EDSS<sup>25</sup>. Interestingly we found that non-white ethnicity is associated with lower PRO scores. Generally non-white populations have similar disability to white populations. However socioeconomic factors including participation, health literacy and health behaviours differ in non-white populations. As our population is a volunteer population therefore this non-white population could be biased towards those with a better outcome.<sup>26</sup> Furthermore, we have reinforced the appropriateness of PROs in this setting by using a prospective parallel group analysis to show that PROs related to motor disability worsen over 4 years irrespective of smoking status, as has been previously documented with the EDSS.

We have extended the use of PROs by adapting them for use in time to event analyses. Such analyses are common in MS trials<sup>27</sup>. Regular data capture has allowed us to identify a population in whom smoking status can be confirmed at each data timepoint and in whom clinically significant PRO step changes can be identified and timestamped over a period of up to 8 years. PROs tied to clinically relevant outcomes in this way offer the opportunity to determine the interaction with key potential confounders such as depression and anxiety. Here, we have shown that, uniquely among the tested PROs, anxiety does not worsen over time, even though anxiety is higher in current smokers, improves with smoking cessation and is independently associated with the motor score. This implies that anxiety is not directly linked to MS. Depression on the other hand, does appear to be linked with the disease itself, worsening over time and, notably, deteriorating more rapidly in former smokers compared to never smokers. There is a potential that depression could drive both continued smoking and lack of exercise.

There are several limitations of our study. The UKMSR is predominantly a self-declared register but here we have confirmed smoking status against independent healthcare team verification. Interestingly, we find that the rate of smoking declaration is higher in the self-reported data than in the clinical documentation. This discrepancy raises questions about how clinical teams can target smoking cessation advice if they are not aware of a patient's true smoking status. A further major issue with registries is that selection bias can be augmented when participants are effectively allocating themselves into study groups. Therefore, we cannot exclude the indirect effects of other beneficial health related activity that may go hand in hand with smoking cessation. The UKMSR is representative of the UK MS population<sup>11</sup> but here, by using a subset of the total study population, we find that completing more PROs and with greater regularity is associated with lower rates of smoking. Participants who have completed more PROs also tend to be older, male, and to have more progressive MS. Despite these apparent biases, we are still able to demonstrate the impact of smoking cessation in all populations.

Despite longstanding knowledge that smoking is associated with a poor outcome in MS, we show that the rate of smoking in pwMS is on par with the national rates. The number of former smokers is higher than the national average indicating the rates of smoking may have previously been higher still in pwMS in common with prior populations studied<sup>7,9</sup>. This suggests that pwMS may not be receiving sufficient encouragement and support to stop

smoking. This failure is in common with a number of other conditions in which smoking is known to have a negative impact. Recognition of such a failure has led to calls for advice about smoking cessation to be included in standard clinical guidelines for relevant diseases<sup>28</sup> and adds to the arguments for generating evidence for the effectiveness of smoking cessation interventions<sup>29</sup>. Here we have provided further impetus for pwMS to stop smoking by showing that the rate of motor deterioration is not only accelerated in smokers, but that it returns to the rate of deterioration in non-smokers following smoking cessation.

## Acknowledgements

Ed Holloway and Emma Gray, UK MS Society.

## Competing interests:

Rodgers, Vonberg, Ford, Middleton, Constantinescu, Emsley, Sharrack, Coles, Duddy, Ford H, McLean, Rog, Husseyin, Hobart, Wilson, Galea, Finisku, McDonnell, Kipps, Straukiene, Marta, Schmierer nothing to disclose

Nicholas: Support from advisory boards and travel from Novartis, Roche and Biogen. He has grant support from the UK MS Society and is a member of a NICE HTA committee

Friede: personal fees from Bayer, BiosenseWebster, Boehringer Ingelheim, CSL Behring, Daiichi-Sankyo, Fresenius Kabi, Galapagos, Immunic, Janssen, LivaNova, Novartis, Roche, Vifor; all outside the submitted work.

Chataway: In the last 3 years, JC has received support from the Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by the Canadian MS society. A local principal investigator for commercial trials funded by: Actelion, Biogen, Novartis and Roche; has received an investigator grant from Novartis; and has taken part in advisory boards/consultancy for Azadyne, Biogen, Celgene, Janssen, MedDay, Merck, Novartis and Roche.

Harrower: received support to attend meetings, provide advice for adboards, delivering lectures etc from: Merck Serrono, Biogen, UCB, Eisai, Britannia, Ipsen, Allergan, Merz, Revance, GSK, GWP Pharma, Solvay Health Care

## Contributors Statement:

WJR - Conceptualization (equal), Methodology (equal), Software (lead), Validation (equal), Formal Analysis (equal), Investigation (equal), Data Curation (lead), Writing - Original

- Draft (equal), Writing - Review & Editing (equal), Visualization (lead), Project administration (supporting)
- TF - Conceptualization (equal), Methodology (equal), Validation (equal), Formal Analysis (equal), Investigation (equal), Writing - Original Draft (equal), Writing - Review & Editing (equal)
- FWV - Validation (equal), Formal Analysis (equal), Investigation (equal), Writing - Original Draft (equal), Writing - Review & Editing (equal)
- CSC - Conceptualization (supporting), Writing - Review & Editing (supporting), Data Curation (supporting)
- AC - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- JC - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- MD - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- HE - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- HF - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- LF - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- IG - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- TH - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- JH - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- HH - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- CK - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- MM - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- GM - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- BM - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- ORP - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- DR - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- KS - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- BS - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- AS - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)
- HW - Writing - Review & Editing (supporting), Data Curation (supporting), Funding acquisition (supporting)



DVF - DVF - Writing - Review & Editing (supporting), Resources (supporting), Funding acquisition (equal), Project administration (supporting)

RMM - Conceptualization (equal), Investigation (supporting), Resources (lead), Data Curation (supporting), Supervision (equal), Writing - Original Draft (equal), Writing - Review & Editing (equal), Project administration (equal), Funding acquisition (equal)

RN - Conceptualization (equal), Methodology (equal), Validation (equal), Formal Analysis (equal), Investigation (equal), Data Curation (supporting), Supervision (lead), Writing - Original Draft (equal), Writing - Review & Editing (equal), Project (equal), Funding acquisition (equal), Project administration (equal), Funding acquisition (equal)

## **Funding:**

The UK MS Society, The Berkeley Foundation, The Multiple Sclerosis Trials Collaboration

## **Ethics approval:**

The UK MS Register has research ethics approval from South West Central Bristol Research Ethics Committee 16/SW/0194

## References

1. Emre M, de Decker C. Effects of Cigarette Smoking on Motor Functions in Patients With Multiple Sclerosis. *Arch Neurol*. 1992;49(12):1243-1247. doi:10.1001/archneur.1992.00530360041015
2. Healy BC, Ali EN, Guttmann CRG, et al. Smoking and Disease Progression in Multiple Sclerosis. *Arch Neurol*. 2009;66(7). doi:10.1001/archneurol.2009.122
3. Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. *Neurology*. 2009;73(7):504-510. doi:10.1212/WNL.0b013e3181b2a706
4. Ozcan ME, Asil T, Ince B, et al. Association between smoking and cognitive impairment in multiple sclerosis. *Neuropsychiatr Dis Treat*. Published online September 2014:1715. doi:10.2147/NDT.S68389
5. Tanasescu R, Constantinescu CS, Tench CR, Manouchehrinia A. Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. *Nicotine Tob Res*. 2018;20(5):589-595. doi:10.1093/ntr/ntx084
6. Manouchehrinia A, Weston M, Tench CR, Britton J, Constantinescu CS. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. *J Neurol Neurosurg Psychiatry*. 2014;85(10):1091-1095. doi:10.1136/jnnp-2013-307187
7. Manouchehrinia A, Tench CR, Maxted J, Bibani RH, Britton J, Constantinescu CS. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. *Brain*. 2013;136(7):2298-2304. doi:10.1093/brain/awt139
8. Hernan MA. Cigarette Smoking and the Progression of Multiple Sclerosis. *Brain*. 2005;128(6):1461-1465. doi:10.1093/brain/awh471
9. Ramanujam R, Hedström A-K, Manouchehrinia A, et al. Effect of Smoking Cessation on Multiple Sclerosis Prognosis. *JAMA Neurol*. 2015;72(10):1117. doi:10.1001/jamaneurol.2015.1788
10. Binzer S, McKay KA, Brenner P, Hillert J, Manouchehrinia A. Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study. *Neurology*. 2019;93(24):e2216-e2223. doi:10.1212/WNL.00000000000008617
11. Middleton R, Rodgers W, Chataway J, et al. Validating the Portal Population of the United Kingdom Multiple Sclerosis Register. *Mult Scler Relat Disord*. Published online May 2018. doi:10.1016/j.msard.2018.05.015
12. Pellegrini F, Copetti M, Bovis F, et al. A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. *Mult Scler J*. 2020;26(9):1064-1073. doi:10.1177/1352458519849513
13. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the Impact of MS on Walking Ability: The 12-Item MS Walking Scale (MSWS-12). *Neurology*. 2003;60(1):31-36. doi:10.1212/WNL.60.1.31

14. Hobart J. The Multiple Sclerosis Impact Scale (MSIS-29): A New Patient-Based Outcome Measure. *Brain*. 2001;124(5):962-973. doi:10.1093/brain/124.5.962
15. Mehta L, McNeill M, Hobart J, et al. Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results. *Mult Scler J - Exp Transl Clin*. 2015;1:205521731559699. doi:10.1177/2055217315596993
16. Costelloe L, O'Rourke K, Kearney H, et al. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). *J Neurol Neurosurg Amp Psychiatry*. 2007;78(8):841-844. doi:10.1136/jnnp.2006.105759
17. Phillips GA, Wyrwich KW, Guo S, et al. Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening. *Mult Scler J*. 2014;20(13):1753-1760. doi:10.1177/1352458514530489
18. Raffel J, Wallace A, Gveric D, Reynolds R, Friede T, Nicholas R. Patient-Reported Outcomes and Survival in Multiple Sclerosis: A 10-Year Retrospective Cohort Study Using the Multiple Sclerosis Impact Scale-29. Basu S, ed. *PLOS Med*. 2017;14(7):e1002346. doi:10.1371/journal.pmed.1002346
19. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x
20. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. *Health Technol Assess*. 2009;13(12). doi:10.3310/hta13120
21. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. *The Lancet*. 2014;383(9936):2213-2221. doi:10.1016/S0140-6736(13)62242-4
22. Lemay KR, Tulloch HE, Pipe AL, Reed JL. Establishing the Minimal Clinically Important Difference for the Hospital Anxiety and Depression Scale in Patients With Cardiovascular Disease. *J Cardiopulm Rehabil Prev*. 2019;39(6):E6-E11. doi:10.1097/HCR.0000000000000379
23. Adult smoking habits in the UK: 2019 - Office for National Statistics. Accessed August 17, 2021. <https://www.ons.gov.uk/releases/adultsmokinghabitsintheuk2019>
24. Bovis F, Signori A, Carmisciano L, et al. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas: EDSS Progression Heterogeneity. *Ann Neurol*. 2018;84(4):621-625. doi:10.1002/ana.25323
25. Kalincik T, Diouf I, Sharmin S, et al. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. *Neurology*. Published online December 28, 2020:10.1212/WNL.0000000000011242. doi:10.1212/WNL.0000000000011242

26. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? *Neurology*. 2006;66(8):1235-1240. doi:10.1212/01.wnl.0000208505.81912.82
27. EMA. Clinical investigation of medicinal products for the treatment of multiple sclerosis. European Medicines Agency. Published March 31, 2015. Accessed February 2, 2021. <https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-multiple-sclerosis>
28. Ekezie W, Murray RL, Agrawal S, Bogdanovica I, Britton J, Leonardi-Bee J. Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review. *Clin Med*. 2020;20(6):551-559. doi:10.7861/clinmed.2020-0359
29. Marck CH, das Nair R, Grech LB, Borland R, Constantinescu CS. Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success. *Mult Scler J*. 2020;26(3):266-271. doi:10.1177/1352458519858730

## Figure legends

**Figure 1.** Boxplots demonstrating the effect of smoking cessation (**A**) and smoking amount (light, moderate, heavy) in current (**B**) and former smokers (**C**) for the MSIS-29-phy (panel 1), MSWS-12 (panel 2), HADS-anxiety (panel 3) and HADS-depression (panel 4).

**Figure 2.** Parallel group analysis of mean change ( $\pm$ standard error) for former (grey line), current (black dashes) and never (light grey dots) smokers. Plots are over 4 years for MSIS-29-Phys (A: n=731:382 never-smokers, 105 current-smokers and 244 former smokers), MSWS-12 (B: n=573: 317 never-smokers, 81 current-smokers and 175 former smokers), HADS-anxiety (C) and HADS-depression (D: n=766: 407 never-smokers, 107 current-smokers and 252 former smokers).

**Figure 3.** Cumulative event (1-Kaplan-Meier) curves for MSIS-29-phy (A: n=4436) and MSWS-12 (B: n=3902). Being a current smoker (dots) was associated with a higher rate of worsening events in both MSIS-29-Phys (Wald test chi-square, [df=2] =13.32, p=0.0013; median time [95%CI]: 673 days [600, 787]) and MSWS-12 (Wald test chi-square, [df=2] =10.16, p=0.0061; median time 936 days [803, 1135]) compared to never (line; MSIS-phys median time 883 days [819, 960]; MSWS-12 median time 1131 [1035, 1317]) and former smokers (dashes; MSIS-phys median time 829 days [772, 930]; MSWS-12 median time 1250 [1029, 14567]).

**Figure 4.** Cumulative event (1-Kaplan-Meier) curves for HADS-anxiety (A: n=4511) and HADS-depression (B: n=4511). Being a current smoker (dots) was associated with a higher rate of both HADS-anxiety (Wald test chi-square, [df=2] =12.68, p=0.0017; median time 907 days [742, 1239]) and -depression (Wald test chi-square, [df=2] =54.25, p<0.0001; median time 760 days [629, 934]). PRO worsening events compared to never (line; HADS-anxiety median time 1318 days [1168, 1519]; HADS-depression median time 1392 [1207, 1563]) and former smokers (dashes; HADS-anxiety median time 1318 days [1118, 1483]; HADS-depression median time 1110 [1034, 1270]).




Figure 1




Figure 2




Figure 3

169x254mm (300 x 300 DPI)






Figure 4

169x254mm (300 x 300 DPI)

Table 1 Demographics and PRO outcomes of the total population with a given smoking status (n=7983), the time-to-event (n=4642) and parallel group (n=923) population

	N, smoking status p value			Never			Former			Current		
	Total	Time to event	Parallel	Total	Time to event	Parallel	Total	Time to event	Parallel	Total	Time to event	Parallel
	n below	n below	n below	(n = 3853)	(n = 2378)	(n = 487)	(n = 2815)	(n = 1589)	(n = 309)	(n = 1315)	(n = 675)	(n = 127)
Age at Baseline, mean (SD)	7983	4642	923	48 (11.5)	49.6 (11)	51.5 (10)	50.7 (11.2)	52.6 (10.7)	54.7 (9.8)	45.3 (11.1)	47.3 (10.9)	49.1 (10.6)
Time Since MS Onset, mean (SD)	7826	4596	919	13.3 (10.6)	14.3 (10.8)	16.1 (10.7)	15.6 (11.8)	16.5 (12)	17.5 (11.4)	11.9 (9.8)	13 (10.2)	14.2 (10.5)
Gender: female, N (%)	7983	4642	923	3016 (78.3)	1856 (78)	375 (77)	1934 (68.7)	1070 (67.3)	185 (59.9)	940 (71.5)	457 (67.7)	84 (66.1)
MS at Diagnosis: Known-Progressive, N (%)	7983	4642	923	682 (17.7)	459 (19.3)	116 (23.8)	602 (21.4)	380 (23.9)	98 (31.7)	225 (17.1)	134 (19.9)	32 (25.2)
On DMT: Known-DMT, N (%)	7983	4642	923	1167 (30.3)	810 (34.1)	171 (35.1)	656 (23.3)	407 (25.6)	73 (23.6)	359 (27.3)	209 (31)	41 (32.3)
On Highly Active DMT N(%)	7983	4642	923	59 (1.5)	38 (1.6)	6 (1.2)	38 (1.3)	21 (1.3)	2 (0.6)	25 (1.9)	13 (1.9)	4 (3.1)
Black, Asian and minority ethnic, N (%)	7534	4408	868	271 (7)	137 (5.8)	17 (3.5)	177 (6.3)	75 (4.7)	7 (2.3)	118 (9)	57 (8.4)	9 (7.1)
MSIS-29-Phys, median [IQR]	7840	4436	922	36.7 [16.7–60]	36.7 [18.3–58.6]	40.6 [21.7–61.7]	43.3 [23.3–64.4]	45 [25–65]	48.3 [28.3–66.7]	48.3 [26.7–69.1]	50 [30–70]	48.8 [30–65.6]
MSWS-12, median [IQR]	7318	3902	885	47.6 [14.3–78.6]	50 [16.7–78.6]	61.9 [26.2–85.7]	59.5 [23.8–85.7]	59.5 [26.2–85.7]	71.4 [40.5–90.5]	59.5 [28.6–85.7]	64.3 [31–85.7]	66.7 [39.3–86.9]
HADS Anxiety, median [IQR]	7923	4511	923	7 [4–10]	7 [4–10]	7 [4–10]	8 [5–11]	7 [5–11]	7 [4–9]	9 [6–12]	9 [6–12]	8 [5–11]
HADS Depression, median [IQR]	7923	4511	923	6 [3–9]	6 [3–9]	5 [3–8.5]	6 [4–9]	6 [4–10]	6 [4–9]	8 [5–11]	7 [5–10]	7 [4–10]

SD – standard deviation; IQR –interquartile range.

Table 2 Multivariable linear regression of retrospective data (MSIS-29-Phys n=7840, MSWS-12 n= 7318, HADS n = 7923)

		MSIS-29-Phys		MSWS-12	
		Estimate, 95% CI	p-value	Estimate, 95% CI	p-value
(Intercept)		<b>31.45, [28.45, 34.44]</b>	<b>&lt;0.0001</b>	<b>26.25, [22.36, 30.13]</b>	<b>&lt;0.0001</b>
Smoking status (ref: Never)	Former	-0.21, [-2.12, 1.7]	0.83	-0.63, [-3.11, 1.84]	0.62
	Current	<b>4.65, [1.87, 7.42]</b>	<b>0.001</b>	<b>3.68, [0.09, 7.28]</b>	<b>0.044</b>
Age		0, [-0.07, 0.07]	0.97	<b>0.24, [0.15, 0.32]</b>	<b>&lt;0.0001</b>
Gender (ref: Female)	Male	-0.86, [-2.12, 0.39]	0.18	1.04, [-0.6, 2.68]	0.21
Time since onset		<b>0.54, [0.48, 0.59]</b>	<b>&lt;0.0001</b>	<b>0.7, [0.62, 0.78]</b>	<b>&lt;0.0001</b>
Progressive (ref: No)	Yes	<b>12.67, [11.14, 14.2]</b>	<b>&lt;0.0001</b>	<b>20.9, [18.87, 22.93]</b>	<b>&lt;0.0001</b>
Treatment (Ref: No Treatment)	Normally Active	<b>-5.41, [-6.71, -4.12]</b>	<b>&lt;0.0001</b>	<b>-6.37, [-8.02, -4.72]</b>	<b>&lt;0.0001</b>
	Highly Active	<b>-6.63, [-11.06, -2.2]</b>	<b>0.0034</b>	<b>-6.37, [-11.9, -0.85]</b>	<b>0.024</b>
Black, Asian, Minority Ethnic (ref: No)	Yes	<b>-3.71, [-5.83, -1.59]</b>	<b>0.00059</b>	<b>-5.54, [-8.29, -2.79]</b>	<b>&lt;0.0001</b>
Pack Years		<b>0.19, [0.11, 0.26]</b>	<b>&lt;0.0001</b>	<b>0.21, [0.11, 0.31]</b>	<b>&lt;0.0001</b>
		HADS-Anxiety		HADS-Depression	
(Intercept)		<b>11.79, [11.27, 12.3]</b>	<b>&lt;0.0001</b>	<b>6.7, [6.21, 7.2]</b>	<b>&lt;0.0001</b>
Smoking status (ref: Never)	Former	0.15, [-0.18, 0.47]	0.38	-0.13, [-0.45, 0.18]	0.41
	Current	<b>0.79, [0.31, 1.26]</b>	<b>0.0012</b>	<b>0.74, [0.28, 1.2]</b>	<b>0.0015</b>
Age		<b>-0.09, [-0.1, -0.07]</b>	<b>&lt;0.0001</b>	<b>-0.02, [-0.03, -0.01]</b>	<b>0.00016</b>
Gender (ref: Female)	Male	<b>-0.84, [-1.05, -0.62]</b>	<b>&lt;0.0001</b>	0.06, [-0.14, 0.27]	0.56
Time since onset		<b>0.02, [0.01, 0.03]</b>	<b>0.0031</b>	<b>0.03, [0.02, 0.04]</b>	<b>&lt;0.0001</b>
Progressive (ref: No)	Yes	<b>0.14, [-0.12, 0.4]</b>	<b>0.29</b>	<b>0.81, [0.56, 1.06]</b>	<b>&lt;0.0001</b>
Treatment (Ref: No Treatment)	Normally Active	<b>-0.3, [-0.52, -0.08]</b>	<b>0.0081</b>	<b>-0.52, [-0.74, -0.31]</b>	<b>&lt;0.0001</b>
	Highly Active	<b>-1.52, [-2.27, -0.76]</b>	<b>&lt;0.0001</b>	<b>-1.25, [-1.98, -0.52]</b>	<b>0.00075</b>
Black, Asian, Minority Ethnic (ref: No)	Yes	-0.18, [-0.54, 0.18]	0.32	-0.24, [-0.59, 0.11]	0.18
Pack Years		<b>0.03, [0.01, 0.04]</b>	<b>&lt;0.0001</b>	<b>0.03, [0.02, 0.05]</b>	<b>&lt;0.0001</b>

Downloaded from https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awab385/6384574 by guest on 04 March 2022

Table 3 Cox regression models for the time to worsening of the PROs (hazard ratios and 95% confidence intervals)

Hazard ratio,95% CI		MSIS-29-Phys	MSWS-12	HADS-Anxiety	HADS-Depression
Smoking status (ref: Never)	Former	1.02, [0.88, 1.17]	0.97, [0.84, 1.13]	1.02, [0.88, 1.17]	1.01, [0.88, 1.17]
	Still	<b>1.3, [1.04, 1.62]</b>	1.16, [0.92, 1.47]	<b>1.25, [1, 1.57]</b>	<b>1.25, [1, 1.56]</b>
PRO baseline score		0.99, [0.99, 1]	<b>1, [1, 1.01]</b>	1, [0.99, 1.01]	1, [0.99, 1.01]
Max number of PROs		1, [0.99, 1.01]	1, [0.99, 1.01]	1, [0.99, 1]	1, [0.99, 1.01]
Age at baseline (Years)		<b>1, [1, 1.01]</b>	1, [0.99, 1]	<b>1, [1, 1.01]</b>	<b>1, [1, 1.01]</b>
Gender (ref: Female)	Male	0.97, [0.88, 1.06]	0.96, [0.87, 1.06]	0.98, [0.89, 1.07]	0.98, [0.89, 1.07]
Time Since Onset (Years)		<b>1, [1, 1.01]</b>	1, [0.99, 1]	1, [0.99, 1]	1, [0.99, 1]
Progressive (ref: No)	Yes	<b>1.22, [1.09, 1.36]</b>	1.05, [0.94, 1.18]	<b>1.11, [1, 1.24]</b>	<b>1.11, [1, 1.24]</b>
Treatment (Ref: No Treatment)	Normally Active	1, [0.91, 1.1]	1.06, [0.96, 1.17]	1.03, [0.94, 1.13]	1.03, [0.94, 1.14]
	Highly Active	1.11, [0.77, 1.62]	1.1, [0.76, 1.6]	1.13, [0.77, 1.64]	1.13, [0.78, 1.65]
Black, Asian, Minority Ethnic (ref: No)	Yes	0.86, [0.72, 1.04]	0.85, [0.7, 1.04]	0.88, [0.73, 1.06]	0.88, [0.74, 1.06]
Pack Years		<b>1, [1, 1.01]</b>	1, [0.99, 1.01]	1, [0.99, 1.01]	1, [0.99, 1.01]

Table 4 Cox regression models for the time to worsening of the PROs incorporating anxiety and depression (hazard ratios and 95% confidence intervals)

Hazard ratio,95% CI		MSIS-29-Phys	MSWS-12	HADS-Anxiety	HADS-Depression
Smoking status (ref: Never)	Former	1.02, [0.88, 1.18]	0.98, [0.84, 1.14]	1, [0.86, 1.16]	0.99, [0.85, 1.15]
	Still	<b>1.28, [1.02, 1.6]</b>	1.16, [0.92, 1.47]	<b>1.27, [1.01, 1.6]</b>	1.22, [0.97, 1.55]
MSIS-29-Phys		<b>0.99, [0.99, 0.99]</b>		<b>0.97, [0.96, 0.97]</b>	<b>0.96, [0.96, 0.97]</b>
MSWS-12			<b>1, [1, 1.01]</b>	<b>1.03, [1.02, 1.03]</b>	<b>1.03, [1.02, 1.03]</b>
HADS-Anxiety		0.99, [0.98, 1.01]	0.99, [0.98, 1.01]	1.04, [1.02, 1.05]	
HADS-Depression		<b>1.05, [1.03, 1.06]</b>	0.99, [0.98, 1.01]		<b>1.05, [1.04, 1.07]</b>
Max MSIS-29		1.02, [0.97, 1.07]		1.02, [0.97, 1.07]	1.01, [0.96, 1.07]
Max MSWS-12			<b>1.03, [1, 1.05]</b>	1.01, [0.99, 1.03]	1.01, [0.99, 1.03]
Max HADS		0.98, [0.94, 1.03]	<b>0.97, [0.96, 0.99]</b>	0.97, [0.93, 1.03]	0.98, [0.93, 1.03]
Age at baseline		<b>1, [1, 1.01]</b>	1, [0.99, 1]	1, [0.99, 1]	1, [0.99, 1]
Gender (ref: Female)	Male	0.94, [0.86, 1.04]	0.96, [0.87, 1.05]	0.94, [0.86, 1.04]	<b>0.9, [0.82, 0.99]</b>
Time since onset		<b>1, [1, 1.01]</b>	1, [0.99, 1]	1, [0.99, 1]	1, [0.99, 1]
Progressive (ref: No)	Yes	<b>1.24, [1.12, 1.39]</b>	1.06, [0.94, 1.19]	1.01, [0.89, 1.13]	1.02, [0.91, 1.15]
Treatment (Ref: No Treatment)	Normally Active	0.99, [0.9, 1.09]	1.05, [0.95, 1.16]	1.03, [0.93, 1.14]	1.02, [0.93, 1.13]
	Highly Active	1.11, [0.76, 1.62]	1.07, [0.73, 1.57]	1.06, [0.74, 1.53]	1.07, [0.75, 1.54]
Black, Asian, Minority Ethnic (ref: No)	Yes	0.86, [0.72, 1.03]	0.85, [0.7, 1.04]	0.87, [0.71, 1.05]	0.87, [0.72, 1.06]
Pack Years		<b>1, [1, 1.01]</b>	<b>1, [1, 1.01]</b>	<b>1, [1, 1.01]</b>	<b>1, [1, 1.01]</b>